Anaptysbio Stock Price, News & Analysis

AnaptysBio, Inc. (Nasdaq: ANAB) is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The company develops antibody-based drug candidates and has also discovered and out-licensed multiple therapeutic antibodies under financial collaborations. In addition to its internal pipeline, AnaptysBio is eligible for milestone and royalty payments from partnered programs, including a PD-1 antagonist and an IL-36 receptor antagonist.

Core focus and therapeutic area

AnaptysBio describes itself as a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its work centers on antibody drug candidates that modulate immune pathways thought to drive these conditions. The company’s activities include advancing its own clinical programs and entering into collaboration and license agreements under which partners develop and commercialize certain antibodies discovered by AnaptysBio.

Pipeline programs

According to multiple company press releases, AnaptysBio’s pipeline includes:

• Rosnilimab, described as a pathogenic T cell depleter. It completed a Phase 2b trial for the treatment of rheumatoid arthritis. Rosnilimab has also been evaluated in a Phase 2 trial for moderate-to-severe ulcerative colitis, where a global study did not meet primary or key secondary endpoints at Week 12 and the ulcerative colitis trial is being discontinued.
• ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease, with company communications noting plans to expand development into an additional inflammatory indication.
• ANB101, a BDCA2 modulator, in a Phase 1a trial in healthy volunteers.

Company disclosures highlight that rosnilimab has been studied in a global Phase 2b rheumatoid arthritis trial. Reported data include statistically significant and clinically meaningful efficacy on the primary endpoint and other response measures at Week 12, with additional data describing deepening responses through Week 28 and durability off drug through Week 38, alongside a reported favorable safety and tolerability profile in that study.

Out-licensed antibody programs and royalty assets

AnaptysBio has discovered and out-licensed several therapeutic antibodies in financial collaborations:

• A PD-1 antagonist, Jemperli (dostarlimab-gxly), licensed to GSK (through Tesaro, an oncology-focused biopharmaceutical company now part of GSK). Under a Collaboration and Exclusive License Agreement entered in March 2014, Tesaro is developing Jemperli as a monotherapy and in combination with additional therapies for various solid tumor indications. AnaptysBio is eligible to receive tiered royalties on net sales of Jemperli, with a royalty term that extends at least through expiration of composition of matter coverage on the molecule, which company disclosures state expires in 2035 in the U.S. and 2036 in the EU.
• An IL-36 receptor antagonist, imsidolimab, licensed to Vanda Pharmaceuticals under an exclusive global license for development and commercialization. Vanda has announced submission of a Biologics License Application to the U.S. Food and Drug Administration for imsidolimab for generalized pustular psoriasis, and Vanda holds the exclusive global license from AnaptysBio.

Company materials also describe a royalty monetization arrangement under which Jemperli receivables from Tesaro are payable to Sagard up to specified capped amounts, after which those receivables would revert to AnaptysBio.

Planned separation of businesses

AnaptysBio has announced an intent to separate its biopharma operations from what it describes as substantial royalty assets by the end of 2026. In its communications, the company states that this separation is intended to create two independent, publicly traded entities with different business objectives and opportunities:

• A royalty management company that would manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a stated focus on protecting and returning their value to shareholders.
• A biopharma operations company that would focus on development and potential commercialization of immunology therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101.

Company disclosures indicate that the board of directors approved plans to explore this separation and that the separation is expected to occur by the end of 2026, subject to the company’s ongoing process.

Collaboration agreement and litigation with Tesaro and GSK

AnaptysBio’s relationship with Tesaro and GSK is governed by a Collaboration and Exclusive License Agreement under which Tesaro agreed to certain exclusivity and commercial efforts obligations regarding Jemperli. AnaptysBio has filed a Verified Complaint in Delaware Chancery Court contending that Tesaro breached, and GSK induced Tesaro to breach, multiple material terms of that agreement, including exclusivity provisions and obligations to use commercially reasonable efforts to obtain an optimum commercial return for Jemperli. Tesaro and GSK have filed their own complaint alleging that AnaptysBio breached the collaboration agreement, and AnaptysBio has filed a motion to dismiss Tesaro’s anticipatory breach of contract claim, asserting that it has not repudiated the agreement and has sought to vindicate its contract rights. A trial in the Delaware Chancery Court is anticipated in July 2026, and AnaptysBio states that milestone and royalty payment obligations under the collaboration continue to be due during the proceedings.

Stock repurchase plan and capital allocation

Company filings and press releases describe a stock repurchase plan under which AnaptysBio’s board authorized repurchases of its outstanding common stock. An amendment approved in November 2025 allows the company to repurchase up to an additional specified dollar amount of its common stock, in addition to amounts remaining under a prior authorization. The company has disclosed the number of shares repurchased and the percentage of shares outstanding represented by those repurchases at the time of the disclosure. The repurchase plan may be executed through open market transactions or other methods in accordance with applicable securities regulations, and may be suspended or discontinued at any time.

Clinical development and regulatory interactions via partners

Through its collaborations, AnaptysBio’s discovered antibodies are being advanced in late-stage clinical development and regulatory processes by partners. Jemperli is being developed by GSK and Tesaro as a monotherapy and in combination regimens for solid tumors, with GSK publicly communicating its commercial performance and peak sales guidance. Vanda has announced Phase 3 data and a Biologics License Application submission for imsidolimab in generalized pustular psoriasis and has requested priority review, while holding the exclusive global license from AnaptysBio.

Exchange listing and sector classification

AnaptysBio’s common stock trades on Nasdaq under the symbol ANAB. The company is described in the provided data as operating in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. Its disclosures consistently characterize AnaptysBio as a clinical-stage biotechnology company focused on immunology therapeutics, with both internal clinical programs and partnered antibody assets that generate or may generate royalties and milestones.

FAQs